What this Trial Is About

Researchers are studying how the drug Filgotinib works to reduce pain in patients with moderate to severe active rheumatoid arthritis (RA). They focus on understanding pain pathways in the brain and how these relate to inflammation and nervous system sensitization. The study explores the role of brain connectivity and neurotransmitters linked to pain, especially pathways seen in conditions like fibromyalgia, to explain Filgotinib's rapid pain relief effects. This is an observational test-retest study where patients prescribed Filgotinib will be evaluated using advanced 7 Tesla MRI brain imaging. The research targets specific brain networks involved in pain processing, such as the Default Mode Network-insula and dorsal attention network-left inferior parietal lobule connections, along with measuring insular glutamate levels. These imaging assessments occur at baseline and after 12 weeks of treatment to observe changes in central nervous system pain sensitization. Participants will undergo brain MRI scans and be monitored for pain-related brain activity and inflammation markers over 12 weeks. The main outcomes include changes in brain connectivity and glutamate levels measured by MRI. Researchers will also assess clinical responses and safety during this period. The study involves adults aged 18 to 74 who have been prescribed Filgotinib for RA and can complete MRI procedures.

7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis